A comprehensive view of Grifols Worldwide. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Grifols announces approval of Xembify, its innovative 20% subcutaneous immunoglobulin, in several EU member states and in the UK; product is a treatment for certain immunodeficiencies, rolling out in Q3 2022

A combination of remdesivir with hIVIG not more effective than remdesivir alone for treating adults hospitalized with COVID-19; safety outcomes 1.6 time worse for patients who had SARS-CoV-2 neutralizing antibodies before hIVIG treatment; study

Grifols announces inclusion on the Bloomberg Gender-Equality Index, recognizing commitment to gender equity; 60% of Grifols' team is made up of women, with a target for 50% of senior management made up of women by 2030

Grifols announces acquisition of its first plasma donation center in Canada, part of company's commitment to increase availability of plasma medicines in the country; donation center in Winnipeg, Manitoba, was acquired for US$4M cash

Grifols enters agreement to sell its 87% stake in VCN Biosciences, valued at up to US$75M, to Synthetic Biologics; company expects to close transaction in Q1 2022

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count